ometendoОжирение и метаболизмObesity and metabolism2071-87132306-5524Endocrinology Research Centre10.14341/2071-8713-4846ometendo-4846Research ArticleСтатьиArticlesСовременные подходы к диагностике и лечению артериальной гипертензииSovremennye podkhody k diagnostike i lecheniyu arterial'noy gipertenziiPodzolkovV I-BulatovV A-NapalkovD A-20051509200523№3 (2005)210Copyright © Podzolkov V.I., Bulatov V.A., Napalkov D.A., 20052005Podzolkov V.I., Bulatov V.A., Napalkov D.A.Podzolkov V.I., Bulatov V.A., Napalkov D.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.omet-endojournals.ru/jour/article/view/4846ReferencesGuidelines Subcommittee. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J. Hypertens. 2003; 21: 1011-1053.Guidelines Subcommittee. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J. Hypertens. 2003; 21: 1011-1053.Профилактика, диагностика и лечение артериальной гипертензии. Российские рекомендации (второй пересмотр). Кардиоваск. тер. и профил. 2004 (приложение).Профилактика, диагностика и лечение артериальной гипертензии. Российские рекомендации (второй пересмотр). Кардиоваск. тер. и профил. 2004 (приложение).Hansson L., Zanchetti A., Carruthers S.G., et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 1998; 351: 1755-1762.Hansson L., Zanchetti A., Carruthers S.G., et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 1998; 351: 1755-1762.Estacio R.O., Jeffers B.W., Hiatt W.R., et al. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. N. Engl. J. Med. 1998; 338: 645-652.Estacio R.O., Jeffers B.W., Hiatt W.R., et al. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. N. Engl. J. Med. 1998; 338: 645-652.UK Prospective Diabetes Study. Tight blood pressure control and risk of macrovas- cular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ 1998; 317: 703-713.UK Prospective Diabetes Study. Tight blood pressure control and risk of macrovas- cular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ 1998; 317: 703-713.PROGRESS Collaborative Study Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet 2001; 358: 1033-1041.PROGRESS Collaborative Study Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet 2001; 358: 1033-1041.Yusuf S., Sleight P., Pogue J., et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N. Engl. J. Med. 2000; 342: 145-153.Yusuf S., Sleight P., Pogue J., et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N. Engl. J. Med. 2000; 342: 145-153.Schrier R.W., Estacio R.O., Esler A., Mehler P. Effects of aggressive blood pres- sure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes. Kidney Int. 2002; 61: 1086-1097.Schrier R.W., Estacio R.O., Esler A., Mehler P. Effects of aggressive blood pres- sure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes. Kidney Int. 2002; 61: 1086-1097.Chobanian A.V., Bakris G.L., Black H.R., et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003; 289: 2560-2572.Chobanian A.V., Bakris G.L., Black H.R., et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003; 289: 2560-2572.Major outcomes in high-risk hypertensive patients randomized to angiotensin- converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALL- HAT). JAMA 2002; 288: 2981-2997.Major outcomes in high-risk hypertensive patients randomized to angiotensin- converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALL- HAT). JAMA 2002; 288: 2981-2997.World Health Organization-International Society of Hypertension Guidelines for the Management of Hypertension. Guidelines Subcommittee. J. Hypertens 1999; 17: 151-183.World Health Organization-International Society of Hypertension Guidelines for the Management of Hypertension. Guidelines Subcommittee. J. Hypertens 1999; 17: 151-183.Gosse P., Sheridan D.J., Zannad F. et al. Regression of left ventricular hypertro- phy in hypertensive patients treated with indapamide SR 1.5 mg versus enalapril 20 mg: the LIVE study. J. Hypertens 2000; 18: 1465-1540.Gosse P., Sheridan D.J., Zannad F. et al. Regression of left ventricular hypertro- phy in hypertensive patients treated with indapamide SR 1.5 mg versus enalapril 20 mg: the LIVE study. J. Hypertens 2000; 18: 1465-1540.Marre M., Puig J.G., Kokot F. et al. Equivalence of indapamide SR and enalapril on microalbuminuria reduction in hypertensive patients with type 2 diabetes: the NESTOR Study. J. Hypertens. 2004; 22: 1613-1622.Marre M., Puig J.G., Kokot F. et al. Equivalence of indapamide SR and enalapril on microalbuminuria reduction in hypertensive patients with type 2 diabetes: the NESTOR Study. J. Hypertens. 2004; 22: 1613-1622.Ambrosioni E., Safar M., Degaute J.P. et al. Low-dose antihypertensive therapy with 1.5 mg sustained-release indapamide: results of randomised double-blind controlled studies. European study group. J. Hypertens. 1998; 16: 1677-1684.Ambrosioni E., Safar M., Degaute J.P. et al. Low-dose antihypertensive therapy with 1.5 mg sustained-release indapamide: results of randomised double-blind controlled studies. European study group. J. Hypertens. 1998; 16: 1677-1684.Salpeter S.R., Ormiston T.M., Salpeter E.E. Cardioselective beta-blockers in patients with reactive airway disease: a meta-analysis. Ann. Intern. Med. 2002; 137: 715-725.Salpeter S.R., Ormiston T.M., Salpeter E.E. Cardioselective beta-blockers in patients with reactive airway disease: a meta-analysis. Ann. Intern. Med. 2002; 137: 715-725.Ko D.T., Hebert P.R., Coffey C.S. et al. Beta-blocker therapy and symptoms of depression, fatigue, and sexual dysfunction. JAMA 2002; 288: 351-357.Ko D.T., Hebert P.R., Coffey C.S. et al. Beta-blocker therapy and symptoms of depression, fatigue, and sexual dysfunction. JAMA 2002; 288: 351-357.Grimm R.H., Jr., Grandits G.A., Cutler J.A. et al. Relationships of quality-of-life measures to long-term lifestyle and drug treatment in the Treatment of Mild Hypertension Study. Arch. Intern. Med. 1997; 157: 638-648.Grimm R.H., Jr., Grandits G.A., Cutler J.A. et al. Relationships of quality-of-life measures to long-term lifestyle and drug treatment in the Treatment of Mild Hypertension Study. Arch. Intern. Med. 1997; 157: 638-648.Подзолков В.И., Можарова Л.Г. Применение селективного пролонгированно го b-блокатора с вазодилатирующими свойствами целипролола у больных с эссенциальной гипертензией. Кардиология 2002; №10: 22-26.Подзолков В.И., Можарова Л.Г. Применение селективного пролонгированно го b-блокатора с вазодилатирующими свойствами целипролола у больных с эссенциальной гипертензией. Кардиология 2002; №10: 22-26.Dahlof B., Pennert K., Hansson L. Reversal of left ventricular hypertrophy in hyper- tensive patients. A metaanalysis of 109 treatment studies. Am. J. Hypertens. 1992; 5: 95-110.Dahlof B., Pennert K., Hansson L. Reversal of left ventricular hypertrophy in hyper- tensive patients. A metaanalysis of 109 treatment studies. Am. J. Hypertens. 1992; 5: 95-110.Schmieder R.E., Martus P., Klingbeil A. Reversal of left ventricular hypertrophy in essential hypertension. A meta-analysis of randomized double-blind studies. JAMA 1996; 275: 1507-1520.Schmieder R.E., Martus P., Klingbeil A. Reversal of left ventricular hypertrophy in essential hypertension. A meta-analysis of randomized double-blind studies. JAMA 1996; 275: 1507-1520.Cruickshank J.M., Lewis J., Moore V., Dodd C. Reversibility of left ventricular hypertrophy by differing types of antihypertensive therapy. J. Hum. Hypertens. 1992; 6: 85-90.Cruickshank J.M., Lewis J., Moore V., Dodd C. Reversibility of left ventricular hypertrophy by differing types of antihypertensive therapy. J. Hum. Hypertens. 1992; 6: 85-90.Garg R., Yusuf S. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials. JAMA 1995; 273: 1450-1456.Garg R., Yusuf S. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials. JAMA 1995; 273: 1450-1456.Fox K.M. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo- controlled, multicentre trial (the EUROPA study). Lancet 2003; 362: 782-788.Fox K.M. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo- controlled, multicentre trial (the EUROPA study). Lancet 2003; 362: 782-788.Подзолков В.И., Самойленко В.В., Булатов В.А. Антигипертензивная терапия и концепция нефропротекции. Сердце 2003; 2: 128-131.Подзолков В.И., Самойленко В.В., Булатов В.А. Антигипертензивная терапия и концепция нефропротекции. Сердце 2003; 2: 128-131.Dahlof B., Devereux R.B., Kjeldsen S.E., et al. Cardiovascular morbidity and mor- tality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359: 995-1003.Dahlof B., Devereux R.B., Kjeldsen S.E., et al. Cardiovascular morbidity and mor- tality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359: 995-1003.Brenner B.M., Cooper M.E., de Zeeuw D. et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N. Engl. J. Med. 2001; 345: 861-869.Brenner B.M., Cooper M.E., de Zeeuw D. et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N. Engl. J. Med. 2001; 345: 861-869.Рекомендации по профилактике, диагностике и лечению артериальной гипертензии. Артериальная гипертензия 2001; 7 (приложение): 4-16.Рекомендации по профилактике, диагностике и лечению артериальной гипертензии. Артериальная гипертензия 2001; 7 (приложение): 4-16.Гуревич М.А. Артериальная гипертония у пожилых. Руководство для врачей. Москва: МОНИКИ, 2001.Гуревич М.А. Артериальная гипертония у пожилых. Руководство для врачей. Москва: МОНИКИ, 2001.Лазебник Л.Б., Комиссаренко И.А., Милюкова О.М. Артериальная гипертония у пожилых. Москва: Издательство МАИ, 2003.Лазебник Л.Б., Комиссаренко И.А., Милюкова О.М. Артериальная гипертония у пожилых. Москва: Издательство МАИ, 2003.Hanefeld M., Kohler C. The metabolic syndrome and its epidemiologic dimensions in historical perspective. Z. Arztl. Fortbild. Qualitatssich. 2002; 96: 183-188 [abstract].Hanefeld M., Kohler C. The metabolic syndrome and its epidemiologic dimensions in historical perspective. Z. Arztl. Fortbild. Qualitatssich. 2002; 96: 183-188 [abstract].Tripathy D., Carlsson M., Almgren P. et al. Insulin secretion and insulin sensitivity in relation to glucose tolerance: lessons from the Botnia Study. Diabetes 2000; 49: 975-980.Tripathy D., Carlsson M., Almgren P. et al. Insulin secretion and insulin sensitivity in relation to glucose tolerance: lessons from the Botnia Study. Diabetes 2000; 49: 975-980.World Health Organization: Report of a WHO Consultation: Definition, Diagnosis and Classification of Diabetes Mellitus and ins Complications. Geneva: World Health Organization, 1999.World Health Organization: Report of a WHO Consultation: Definition, Diagnosis and Classification of Diabetes Mellitus and ins Complications. Geneva: World Health Organization, 1999.Shen D.C., Shieh S.M., Fuh M.M. et al. Resistance to insulin-stimulated-glucose uptake in patients with hypertension. J. Clin. Endocrinol. Metab. 1988; 66: 580- 583.Shen D.C., Shieh S.M., Fuh M.M. et al. Resistance to insulin-stimulated-glucose uptake in patients with hypertension. J. Clin. Endocrinol. Metab. 1988; 66: 580- 583.Sheu W.H., Shieh S.M., Fuh M.M. et al. Insulin resistance, glucose intolerance, and hyperinsulinemia. Hypertriglyceridemia versus hypercholesterolemia. Arterioscler. Thromb. 1993; 13: 367-370.Sheu W.H., Shieh S.M., Fuh M.M. et al. Insulin resistance, glucose intolerance, and hyperinsulinemia. Hypertriglyceridemia versus hypercholesterolemia. Arterioscler. Thromb. 1993; 13: 367-370.Балаболкин М.И., Мамаева Г.Г., Кравченко Т.В., Музыченко В.Г. Артериальная гипертензия у больных сахарным диабетом. Генетические аспекты и особенности терапии. Пособие для врачей. Москва, 2003.Балаболкин М.И., Мамаева Г.Г., Кравченко Т.В., Музыченко В.Г. Артериальная гипертензия у больных сахарным диабетом. Генетические аспекты и особенности терапии. Пособие для врачей. Москва, 2003.Suzuki M., Kanazawa A., Hasegawa M., Harano Y. Improvement of insulin resist- ance in essential hypertension by long-acting Ca antagonist benidipine. Clin. Exp. Hypertens. 1999; 21: 1327-1344.Suzuki M., Kanazawa A., Hasegawa M., Harano Y. Improvement of insulin resist- ance in essential hypertension by long-acting Ca antagonist benidipine. Clin. Exp. Hypertens. 1999; 21: 1327-1344.Kaymaz A.A., Tan H., Altug T., Buyukdevrim A.S. The effects of calcium channel blockers, verapamil, nifedipine and diltiazem, on metabolic control in diabetic rats. Diabetes Res. Clin. Pract. 1995; 28: 201-205.Kaymaz A.A., Tan H., Altug T., Buyukdevrim A.S. The effects of calcium channel blockers, verapamil, nifedipine and diltiazem, on metabolic control in diabetic rats. Diabetes Res. Clin. Pract. 1995; 28: 201-205.Trenkwalder P., Plaschke M., Aulehner R., Lydtin H. Felodipine or hydrochlorothiazide/triamterene for treatment of hypertension in the elderly: effects on blood pressure, hypertensive heart disease, metabolic and hormonal parameters. Blood. Press. 1996; 5: 154-163.Trenkwalder P., Plaschke M., Aulehner R., Lydtin H. Felodipine or hydrochlorothiazide/triamterene for treatment of hypertension in the elderly: effects on blood pressure, hypertensive heart disease, metabolic and hormonal parameters. Blood. Press. 1996; 5: 154-163.Маколкин В.И., Подзолков В.И., Напалков Д.А. Антигипертензивная эффективность пролонгированной формы верапамила у больных метаболическим синдромом. Тез. IX Всеросс. конгр. "Человек и лекарство". Москва, 2002.Маколкин В.И., Подзолков В.И., Напалков Д.А. Антигипертензивная эффективность пролонгированной формы верапамила у больных метаболическим синдромом. Тез. IX Всеросс. конгр. "Человек и лекарство". Москва, 2002.Schrier R.W., Estacio R.O. Additional follow-up from the ABCD trial in patients with type 2 diabetes and hypertension. N. Engl. J. Med. 2000; 343: 1969-1969.Schrier R.W., Estacio R.O. Additional follow-up from the ABCD trial in patients with type 2 diabetes and hypertension. N. Engl. J. Med. 2000; 343: 1969-1969.Sowers J.R. Comorbidity of hypertension and diabetes: the fosinopril versus amlodipine cardiovascular events trial (FACET). Am. J. Cardiol. 1998; 82: 15R-19R.Sowers J.R. Comorbidity of hypertension and diabetes: the fosinopril versus amlodipine cardiovascular events trial (FACET). Am. J. Cardiol. 1998; 82: 15R-19R.Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. UK Prospective Diabetes Study Group. BMJ 1998; 317: 713-720.Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. UK Prospective Diabetes Study Group. BMJ 1998; 317: 713-720.Чазова И.Е., Мычка В.Б. Метаболический синдром и артериальная гипертония. Артериальная гипертензия 2002; 8: 8-16.Чазова И.Е., Мычка В.Б. Метаболический синдром и артериальная гипертония. Артериальная гипертензия 2002; 8: 8-16.Афаунов Р.Х., Конради А.О. Влияние длительной терапии индапамидом-ретард на показатели липидного спекра и уровень артериального давления у больных артериальной гипертензией. Артериальная гипертензия 2002; 8: 24-26.Афаунов Р.Х., Конради А.О. Влияние длительной терапии индапамидом-ретард на показатели липидного спекра и уровень артериального давления у больных артериальной гипертензией. Артериальная гипертензия 2002; 8: 24-26.Lithell H.O. Hyperinsulinemia, insulin resistance, and the treatment of hypertension. Am. J. Hypertens. 1996; 9: 150S-154S.Lithell H.O. Hyperinsulinemia, insulin resistance, and the treatment of hypertension. Am. J. Hypertens. 1996; 9: 150S-154S.Lithell H. Metabolic effects of antihypertensive drugs interacting with the sympathetic nervous system. Eur. Heart J. 1992; 13 Suppl A: 53-57.Lithell H. Metabolic effects of antihypertensive drugs interacting with the sympathetic nervous system. Eur. Heart J. 1992; 13 Suppl A: 53-57.Ольбинская Л.И., Боченков В. Опыт применения агониста имидазолиновых рецепторов моксонидина (Цинта) при долгосрочной терапии артериальной гипертонии у больных сахарным диабетом II типа. Клин. фарм. и тер. 2000; №9: 58-60.Ольбинская Л.И., Боченков В. Опыт применения агониста имидазолиновых рецепторов моксонидина (Цинта) при долгосрочной терапии артериальной гипертонии у больных сахарным диабетом II типа. Клин. фарм. и тер. 2000; №9: 58-60.Мильто А.С., Толкачева В.В., Кобалава Ж.Д. Моксонидин в комбинированной терапии гипертонической болезни с высоким риском сердечно-сосудистых осложнений. Клин. фарм. и тер. 2001; №4: 35-38.Мильто А.С., Толкачева В.В., Кобалава Ж.Д. Моксонидин в комбинированной терапии гипертонической болезни с высоким риском сердечно-сосудистых осложнений. Клин. фарм. и тер. 2001; №4: 35-38.Подзолков В.И., Напалков Д.А., Маколкин В.И. Предикторы возникновения основных факторов сердечно-сосудистого риска у больных с метаболическим синдромом. Атмосфера Кардиология 2003; №4: 3-9.Подзолков В.И., Напалков Д.А., Маколкин В.И. Предикторы возникновения основных факторов сердечно-сосудистого риска у больных с метаболическим синдромом. Атмосфера Кардиология 2003; №4: 3-9.Bath P., Chalmers J., Powers W. et al. International Society of Hypertension (ISH): statement on the management of blood pressure in acute stroke. J. Hypertens. 2003; 21: 665-672.Bath P., Chalmers J., Powers W. et al. International Society of Hypertension (ISH): statement on the management of blood pressure in acute stroke. J. Hypertens. 2003; 21: 665-672.Подзолков В.И., Булатов В.А., Можарова Л.Г., Хомицкая Ю.В. Лечение артериальной гипертонии и ИБС: две болезни - единый подход. РМЖ 2003; 11: 568-1572.Подзолков В.И., Булатов В.А., Можарова Л.Г., Хомицкая Ю.В. Лечение артериальной гипертонии и ИБС: две болезни - единый подход. РМЖ 2003; 11: 568-1572.ACC/AHA 2002 Guideline Update for the Management of Patients With Chronic Stable Angina: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1999 Guidelines for the Management of Patients With Chronic Stable Angina), 2002.ACC/AHA 2002 Guideline Update for the Management of Patients With Chronic Stable Angina: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1999 Guidelines for the Management of Patients With Chronic Stable Angina), 2002.Марцевич С. Роль нитратов в современной терапии сердечно-сосудистых заболеваний. Consilium medicum 2004; 6: 308-312.Марцевич С. Роль нитратов в современной терапии сердечно-сосудистых заболеваний. Consilium medicum 2004; 6: 308-312.Peterson J.C., Adler S., Burkart J.M., et al. Blood pressure control, proteinuria, and the progression of renal disease. The Modification of Diet in Renal Disease Study. Ann. Intern. Med. 1995; 123: 754-762.Peterson J.C., Adler S., Burkart J.M., et al. Blood pressure control, proteinuria, and the progression of renal disease. The Modification of Diet in Renal Disease Study. Ann. Intern. Med. 1995; 123: 754-762.Ощепкова Е.В. Возможности нефропротекции при артериальной гипертонии. Атмосфера Кардиология 2003; №1: 15-18.Ощепкова Е.В. Возможности нефропротекции при артериальной гипертонии. Атмосфера Кардиология 2003; №1: 15-18.Gaede P., Vedel P., Larsen N., et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N. Engl. J. Med. 2003; 348: 383-393.Gaede P., Vedel P., Larsen N., et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N. Engl. J. Med. 2003; 348: 383-393.
The authors declare that there are no conflicts of interest present.